(VIANEWS) – The Market ended the session with GENEURO (GNRO.PA) jumping 9.03% to €1.69 on Wednesday, following the last session’s downward trend. CAC 40 fell 1.35% to €7,315.07, after two successive sessions in a row of losses, on what was an all-around down trend exchanging session today.
About GENEURO
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Earnings Per Share
As for profitability, GENEURO has a trailing twelve months EPS of €-0.51.
Volume
Today’s last reported volume for GENEURO is 4066 which is 313.21% above its average volume of 984.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENEURO’s stock is considered to be overbought (>=80).
Volatility
GENEURO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.86%, a negative 0.93%, and a positive 2.04%.
GENEURO’s highest amplitude of average volatility was 1.71% (last week), 1.66% (last month), and 2.04% (last quarter).
More news about GENEURO (GNRO.PA).
